Trial reportEuropean urology2024
Safety Analyses of the Phase 3 VISION Trial of [
Trial report in European urology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03511664 (VISION), which is not on this map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
VISION: An International, Prospective, Open Label, Multicenter, Randomized Phase 3 Study of 177Lu-PSMA-617 in the Treatment of Patients With Progressive PSMA-positive Metastatic Castration-resistant Prostate Cancer (mCRPC)
Who cites it
24 citing papers in PubMed.
- Final overall survival and safety analyses of the phase III PSMAfore trial of [Annals of oncology : official journal of the European Society for Medical Oncology · 2025Trial
- PSMA-targeted radioligand therapy in prostate cancer: evidence hierarchy, platform maturity of ¹⁷⁷Lu-PSMA-617, and the clinical differentiation challenge for emerging radionuclides.Annals of nuclear medicine · 2026Review
- Real-world evaluation of [European journal of nuclear medicine and molecular imaging · 2026Article
- 177 Lu-PSMA for prostate cancer: progress, challenges and future perspectives.Asian journal of andrology · 2026Review
- Outcome-driven dosimetry optimization for [European journal of nuclear medicine and molecular imaging · 2026Article
- Efficacy, safety, and quality of life outcomes of [International urology and nephrology · 2026Review
- Tumor microenvironment-mediated hematologic toxicity ofWorld journal of urology · 2026Review
- Longitudinal renal function following [¹⁷⁷Lu]Lu-PSMA I&T in metastatic castration-resistant prostate cancer.European journal of nuclear medicine and molecular imaging · 2026Article
- The emerging role of prostate-specific membrane antigen-targeted radioligand therapy in metastatic hormone-sensitive prostate cancer.The oncologist · 2026Review
- Novel therapeutic strategies for metastatic castration‑resistant prostate cancer: Beyond androgen receptor pathway inhibition (Review).International journal of oncology · 2026Review
- Harnessing Folate-Mediated PSMA Targeting for Precision Therapy: An Intelligent Liposomal Nanoplatform Against Prostate Cancer.Pharmaceutics · 2026Article
- Frailty and [Theranostics · 2026Review
- Advancements in Targeted Radiopharmaceuticals: Innovations in Diagnosis and Therapy for Enhanced Cancer Management.Chembiochem : a European journal of chemical biology · 2026Review
- Redefining Prostate Cancer Precision: Radiogenomics, Theragnostics, and AI-Driven Biomarkers.Cancers · 2025Review
- Review
- The molecular blueprint of targeted radionuclide therapy.Nature reviews. Clinical oncology · 2025Review
- Development of [European journal of nuclear medicine and molecular imaging · 2025Article
- Biodistribution and dosimetry of [European journal of nuclear medicine and molecular imaging · 2025Article
- PSMA-based Therapies and Novel Therapies in Advanced Prostate Cancer: The Now and the Future.Current treatment options in oncology · 2025Review
- Influence of dosimetry accuracy on the correlation with treatment outcome in a preliminary PSMA radiopharmaceutical therapy study.European journal of nuclear medicine and molecular imaging · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
BACKGROUND AND
objective[
methodsVISION was an international, open-label study. Patients were randomised 2:1 to receive KEY FINDINGS AND LIMITATIONS: The any-grade TEAE incidence was similar in cycles 1-4 and cycles 5-6. TEAE frequency was similar across all cycles of CONCLUSIONS AND CLINICAL IMPLICATIONS: Longer exposure to PATIENT SUMMARY: For patients with metastatic prostate cancer no longer responding to hormone therapy, an increase in the number of cycles of treatment with a radioactive compound called
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.